Publications by authors named "Kip A West"

18Publications

Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity.

Authors:
Daniel S Leventhal Anna Sokolovska Ning Li Christopher Plescia Starsha A Kolodziej Carey W Gallant Rudy Christmas Jian-Rong Gao Michael J James Andres Abin-Fuentes Munira Momin Christopher Bergeron Adam Fisher Paul F Miller Kip A West Jose M Lora

Nat Commun 2020 06 1;11(1):2739. Epub 2020 Jun 1.

Synlogic, Inc., 301 Binney street, suite 402, Cambridge, Massachusetts, 02142, United States.

View Article and Find Full Text PDF
June 2020

An engineered Nissle improves hyperammonemia and survival in mice and shows dose-dependent exposure in healthy humans.

Authors:
Caroline B Kurtz Yves A Millet Marja K Puurunen Mylène Perreault Mark R Charbonneau Vincent M Isabella Jonathan W Kotula Eugene Antipov Yossi Dagon William S Denney David A Wagner Kip A West Andrew J Degar Aoife M Brennan Paul F Miller

Sci Transl Med 2019 01;11(475)

Synlogic Inc., 301 Binney Street, Cambridge, MA 02142, USA.

View Article and Find Full Text PDF
January 2019

Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria.

Authors:
Vincent M Isabella Binh N Ha Mary Joan Castillo David J Lubkowicz Sarah E Rowe Yves A Millet Cami L Anderson Ning Li Adam B Fisher Kip A West Philippa J Reeder Munira M Momin Christopher G Bergeron Sarah E Guilmain Paul F Miller Caroline B Kurtz Dean Falb

Nat Biotechnol 2018 10 13;36(9):857-864. Epub 2018 Aug 13.

Synlogic Inc., Cambridge, Massachusetts, USA.

View Article and Find Full Text PDF
October 2018

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.

Authors:
Elayne Chan-Penebre Kristy G Kuplast Christina R Majer P Ann Boriack-Sjodin Tim J Wigle L Danielle Johnston Nathalie Rioux Michael J Munchhof Lei Jin Suzanne L Jacques Kip A West Trupti Lingaraj Kimberly Stickland Scott A Ribich Alejandra Raimondi Margaret Porter Scott Nigel J Waters Roy M Pollock Jesse J Smith Olena Barbash Melissa Pappalardi Thau F Ho Kelvin Nurse Khyati P Oza Kathleen T Gallagher Ryan Kruger Mikel P Moyer Robert A Copeland Richard Chesworth Kenneth W Duncan

Nat Chem Biol 2015 Jun 27;11(6):432-7. Epub 2015 Apr 27.

Departments of Biology and Molecular Discovery, Epizyme, Inc., Cambridge, Massachusetts, USA.

View Article and Find Full Text PDF
June 2015

HSP90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer.

Authors:
Brenda C O'Connell Katie O'Callaghan Bonnie Tillotson Mark Douglas Nafeeza Hafeez Kip A West Howard Stern Janid A Ali Paul Changelian Christian C Fritz Vito J Palombella Karen McGovern Jeffery L Kutok

PLoS One 2014 26;9(12):e115228. Epub 2014 Dec 26.

Infinity Pharmaceuticals, Inc., Cambridge, MA, United States of America.

View Article and Find Full Text PDF
August 2015

Hedgehog-Gli pathway activation during kidney fibrosis.

Authors:
Steven L Fabian Radostin R Penchev Benoit St-Jacques Anjali N Rao Petra Sipilä Kip A West Andrew P McMahon Benjamin D Humphreys

Am J Pathol 2012 Apr 17;180(4):1441-53. Epub 2012 Feb 17.

Renal Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article and Find Full Text PDF
April 2012

Starting with the ABCs: Akt in breast cancer.

Authors:
Kip A West Phillip A Dennis

Mol Cancer Ther 2011 Nov;10(11):2031

Infinity Pharmaceuticals, Cambridge, Masschusetts, USA.

View Article and Find Full Text PDF
November 2011

Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.

Authors:
Maurizio Scaltriti Violeta Serra Emmanuel Normant Marta Guzman Olga Rodriguez Alice R Lim Kelly L Slocum Kip A West Varenka Rodriguez Ludmila Prudkin José Jimenez Claudia Aura José Baselga

Mol Cancer Ther 2011 May 7;10(5):817-24. Epub 2011 Mar 7.

Medical Oncology Department, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

View Article and Find Full Text PDF
May 2011

Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo.

Authors:
Bonnie Tillotson Kelly Slocum John Coco Nigel Whitebread Brian Thomas Kip A West John MacDougall Jie Ge Janid A Ali Vito J Palombella Emmanuel Normant Julian Adams Christian C Fritz

J Biol Chem 2010 Dec 12;285(51):39835-43. Epub 2010 Oct 12.

Infinity Pharmaceuticals, Cambridge, Massachusetts 02139, USA.

View Article and Find Full Text PDF
December 2010

Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

Authors:
Birgit Schoeberl Emily A Pace Jonathan B Fitzgerald Brian D Harms Lihui Xu Lin Nie Bryan Linggi Ashish Kalra Violette Paragas Raghida Bukhalid Viara Grantcharova Neeraj Kohli Kip A West Magdalena Leszczyniecka Michael J Feldhaus Arthur J Kudla Ulrik B Nielsen

Sci Signal 2009 Jun 30;2(77):ra31. Epub 2009 Jun 30.

Merrimack Pharmaceuticals, One Kendall Square, Building 700, Cambridge, MA 02139, USA.

View Article and Find Full Text PDF
June 2009

Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.

Authors:
Junji Tsurutani Kip A West Jacqueline Sayyah Joell J Gills Phillip A Dennis

Cancer Res 2005 Sep;65(18):8423-32

Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20889, USA.

View Article and Find Full Text PDF
September 2005

Tobacco carcinogen-induced cellular transformation increases Akt activation in vitro and in vivo.

Authors:
Kip A West Ilona R Linnoila John Brognard Steven Belinsky Curtis Harris Phillip A Dennis

Chest 2004 May;125(5 Suppl):101S-2S

Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20889-5105, USA.

View Article and Find Full Text PDF
May 2004

Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues.

Authors:
S Sianna Castillo John Brognard Pavel A Petukhov Chunyu Zhang Junji Tsurutani Courtney A Granville Min Li Michael Jung Kip A West Joell G Gills Alan P Kozikowski Phillip A Dennis

Cancer Res 2004 Apr;64(8):2782-92

Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.

View Article and Find Full Text PDF
April 2004

Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo.

Authors:
Kip A West Ilona R Linnoila Steven A Belinsky Curtis C Harris Phillip A Dennis

Cancer Res 2004 Jan;64(2):446-51

Cancer Therapeutics Branch, Cell and Cancer Biology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.

View Article and Find Full Text PDF
January 2004

Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance.

Authors:
Amy S Clark Kip A West Peter M Blumberg Phillip A Dennis

Cancer Res 2003 Feb;63(4):780-6

Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20889, USA.

View Article and Find Full Text PDF
February 2003

Activation of the PI3K/Akt pathway and chemotherapeutic resistance.

Authors:
Kip A West S Sianna Castillo Phillip A Dennis

Drug Resist Updat 2002 Dec;5(6):234-48

Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Building 8, Room 5101, 8901 Wisconsin Avenue, Bethesda, MD 20889, USA.

View Article and Find Full Text PDF
December 2002

Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells.

Authors:
Kip A West John Brognard Amy S Clark Ilona R Linnoila Xiaowei Yang Sandra M Swain Curtis Harris Steven Belinsky Phillip A Dennis

J Clin Invest 2003 Jan;111(1):81-90

Cancer Therapeutics Branch, Cell and Cancer Biology Branch, National Cancer Institute, Bethesda, Maryland 20889, USA.

View Article and Find Full Text PDF
January 2003

Paxillin-dependent paxillin kinase linker and p21-activated kinase localization to focal adhesions involves a multistep activation pathway.

Authors:
Michael C Brown Kip A West Christopher E Turner

Mol Biol Cell 2002 May;13(5):1550-65

Department of Cell and Developmental Biology, State University of New York Upstate Medical University, Syracuse 13210, USA.

View Article and Find Full Text PDF
May 2002